Farnesyltransferase inhibitors: A comprehensive review based on quantitative structural analysis

Current Medicinal Chemistry

Volumn 20, Issue 38, 2013, Pages 4888-4923

  Moorthy, N S H N ^a   Sousa, S F ^a   Ramos, M J ^a   Fernandes, P A ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

Anticancer; Farnesyltransferase inhibitors; Lonafarnib; Natural products; QSAR; Tipifarnib

Indexed keywords

1BETA,5BETA EPOXIDE; 3 KETOADOCIAQUINONE B; 8 EPI XANTHATIN; 8 EPI XANTHATIN EPOXIDE; ANTINEOPLASTIC AGENT; BENZOFURAN DERIVATIVE; CAPECITABINE; DOCETAXEL; GLIOTOXIN; IMIDAZOLE DERIVATIVE; LETROZOLE; LONAFARNIB; MANUMYCIN; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE; NATURAL PRODUCT; ORHALQUINONE; PENTAPEPTIDE; PEPTIDOMIMETIC AGENT; PIPERIDINE DERIVATIVE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; RHO FACTOR; SESQUITERPENE LACTONE; TEMOZOLOMIDE; THEAFLAVIN; THIOL DERIVATIVE; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHIUM EXTRACT; XESTOSAPROL C METHYLACETAL; AZD3409; BIOLOGICAL PRODUCT; ENZYME INHIBITOR; FARNESYL TRANS TRANSFERASE; PYRIDINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADVANCED CANCER; ANTIMALARIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER INHIBITION; COLON ADENOCARCINOMA; COLON ADENOMA; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; DRUG DESIGN; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG STRUCTURE; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; IC 50; IN VITRO STUDY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NEUROFIBROMA; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHARMACOPHORE; PLASMODIUM FALCIPARUM; PROGERIA; PROTEIN PRENYLATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; STRUCTURE ACTIVITY RELATION; XANTHIUM; XESTOSPONGIA; YEAST; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CLINICAL TRIAL (TOPIC); METABOLISM; NEOPLASMS; PATHOLOGY;

ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HUMANS; NEOPLASMS; PIPERIDINES; PYRIDINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; QUINOLONES;

EID: 84889569673     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113206660262     Document Type: Review

References (259)

1. Sousa, S.F.; Fernandes, P.A.; Ramos, M.J. Theoretical studies on farnesyltransferase: The distances paradox explained. Proteins: Struct. Function, Bioinformatics, 2007, 66, 205-218. (Pubitemid 44955992)
2. Xie, A.; Sivaprakasam, P.; Doerksen, R.J. 3D-QSAR analysis of antimalarial farnesyltransferase inhibitors based on a 2,5- diaminobenzophenone scaffold. Bioorg. Med. Chem., 2006, 14, 7311-7323. (Pubitemid 44403103)
3. Yokoyama, K.; Trobridge, P.; Buckner, F.S.; Van Voorhis, W.C.; Stuart, K.D.; Gelb, M.H. Protein farnesyltransferase from Trypanosoma brucei. A heterodimer of 61- and 65-kda subunits as a new target for antiparasite therapeutics. J. Biol. Chem., 1998, 273, 26497-26505. (Pubitemid 28471658)
4. Capell, B.C.; Erdos, M.R.; Madigan, J.P.; Fiordalisi, J.J.; Varga, R.; Conneely, K.N.; Gordon, L.B.; Der, C.J.; Cox, A.D.; Collins, F.C. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc. Natl. Aacd. Sci. USA, 2005, 102, 12879-12884. (Pubitemid 41282816)
5. Ohkanda, J.; Buckner, F.S.; Lockman, J.W.; Yokoyama, K.; Carrico, D.; Eastman, R.; Luca-Fradley, K.; Davies, W.; Croft, S.L.; Van Voorhis, W.C.; Gelb, M.H.; Sebti, S.M.; Hamilton, A.D. Design and synthesis of peptidomimetic protein farnesyltransferase inhibitors as anti-Trypanosoma brucei agents. J. Med. Chem., 2004, 47, 432-445. (Pubitemid 38057885)
6. Buckner, F.S.; Eastman, R.T.; Nepomuceno-Silva, J.L.; Speelmon, E.C.; Myler, P.J.; Van Voorhis, W.C.; Yokoyama, K. Cloning, heterologous expression, and substrate specificities of protein farnesyltransferases from Trypanosoma cruzi and Leishmania major. Mol. Biochem. Parasitol., 2002, 122, 181-188. (Pubitemid 34775087)
7. Esteva, M.I.; Kettler, K.; Maidana, C.; Fichera, L.; Ruiz, A.M.; Bontempi, E.J.; Andersson, B.; Dahse, H.M.; Haebel, P.; Ortmann, R.; Klebe, G.; Schlitzer, M. Benzophenone-based farnesyltransferase inhibitors with high activity against Trypanosoma cruzi. J. Med. Chem., 2005, 48, 7186-7191. (Pubitemid 41743631)
8. Troutman, J.M.; Subramanian, T.; Andres, D.A.; Spielmann, H.P. Selective modification of CaaX peptides with ortho-substituted anilinogeranyl lipids by protein farnesyl transferase: Competitive substrates and potent inhibitors from a library of farnesyl diphosphate analogues. Biochemistry, 2007, 46, 11310-11321. (Pubitemid 47556758)
9. Eastman, R.T.; White, J.; Hucke, O.; Bauer, K.; Yokoyama, K.; Nallan, L.; Chakrabarti, D.; Verlinde, C.L.; Gelb, M.H.; Rathod, P.K.; Van Voorhis, W.C. Resistance to a protein farnesyltransferase inhibitor in Plasmodium falciparum. J. Biol. Chem., 2005, 280, 13554-13559. (Pubitemid 40517247)
10. Buckner, F.S.; Eastman, R.T.; Yokoyama, K.; Gelb, M.H.; Van Voorhis, W.C. Protein farnesyl transferase inhibitors for the treatment of malaria and African trypanosomiasis. Curr. Opin. Invest. Drugs, 2005, 6, 791-797. (Pubitemid 41103039)
11. Witzig, T.E.; Tang, H.; Micallef, I.N.M.; Ansell, S.M.; Link, B.K.; Inwards, D.J.; Porrata, L.F.; Johnston, P.B.; Colgan, J.P.; Markovic, S.N.; Nowakowski, G.S.; Thompson, C.A.; Allmer, C.; Maurer, M.J.; Gupta, M.; Weiner, G.; Hohl, R.; Kurtin, P.J.; Ding, H.; Loegering, D.; Schneider, P.; Peterson, K.; Habermann, T.M.; Kaufmann, S.H. Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood, 2011, 118, 4882-4889.
12. Zhang, F.L.; Casey, P.J. Protein prenylation: Molecular mechanisms and functional consequences. Annu. Rev. Biochem., 1996, 65, 241-269. (Pubitemid 26250610)
13. Fletcher, S.; Keaney, E.P.; Cummings, C.G.; Blaskovich, M.A.; Hast, M.A.; Glenn, M.P.; Chang, S.Y.; Bucher, C.J.; Floyd, R.J.; Katt, W.P.; Gelb, M.H.; Van Voorhis, W.C.; Beese, L.S.; Sebti, S.M.; Hamilton, A.D. Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents. J. Med. Chem., 2010, 53, 6867-6888.
14. Wang, L.; Lin, N.H.; Li, Q.; Henry, R.F.; Zhang, H.; Cohen, J.; Gu, W.Z.; Marsh, K.C.; Bauch, J.L.; Rosenberg, S.H.; Sham, H.L. Synthesis of 1H-pyridin-2-one derivatives as potent and selective farnesyltransferase inhibitors. Bioorg. Med. Chem. Lett., 2004, 14, 4603-4606. (Pubitemid 39490275)
15. Hast, M.A.; Fletcher, S.; Cummings, C.G.; Pusateri, E.E.; Blaskovich, M.A.; Rivas, K.; Gelb, M.H.; Van Voorhis, W.C.; Sebti, S.M.; Hamilton, A.D.; Beesel, L.S. Structural basis for binding and selectivity of antimalarial and anticancer ethylenediamine inhibitors to protein farnesyltransferase. Chem. Biol., 2009, 16, 181-192.
16. Ohkanda, J.; Lockman, J.W.; Yokoyama, K.; Gelb, M.H.; Croft, S.L.; Kendrick, H.; Harrell, M.I.; Feagin, J.E.; Blaskovich, M.A.; Sebti, S.M.; Hamilton, A.D. Peptidomimetic inhibitors of protein farnesyltransferase show potent antimalarial activity. Bioorg. Med. Chem. Lett., 2001, 11, 761-764. (Pubitemid 32230674)
17. Gupta, M.K.; Prabhakar, Y.S. QSAR study on tetrahydroquinoline analogues as plasmodium protein farnesyltransferase inhibitors: A comparison of rationales of malarial and mammalian enzyme inhibitory activities for selectivity. Eur. J. Med. Chem., 2008, 43, 2751-2767.
18. Sousa, S.F.; Fernandes, P.A.; Ramos, M.J. Farnesyltransferase inhibitors: A detailed chemical view on an elusive biological problem. Curr. Med. Chem., 2008, 15, 1478-1492. (Pubitemid 351997780)
19. Sousa, S.F.; Fernandes, P.A.; Ramos, M.J., The search for the mechanism of the reaction catalyzed by farnesyltransferase. Chem. Eur. J., 2009, 15, 4243-4247.
20. Margaritora, S.; Cesario, A.; Porziella, V.; Granone, P.; Catassi, A.; Russo, P. Farnesyltransferase inhibitors: overview of their action and role in solid malignancy therapy. Lett. Drug Des. Discov., 2005, 2, 26-35. (Pubitemid 40292590)
21. Moorthy, N.S.H.N.; Sousa, S.F.; Ramos, M.J.; Fernandes, P.A. In silico based structural analysis of some piperidine analogs as farnesyltransferase inhibitors. Med. Chem., 2012, 8, 853-864.
22. Long, S.B.; Casey, P.J.; Beese, L.S. Cocrystal structure of protein farnesytransferase complexed with a farnesyl diphosphate substrate. Biochemistry, 1998, 37, 9612-9618. (Pubitemid 28319605)
23. Kyathanahalli, C.N.; Kowluru, A. A farnesylated G-protein suppresses Akt phosphorylation in INS 832/13 cells and normal rat islets: regulation by pertussis toxin and PGE (2). Biochem. Pharmacol., 2011, 81, 1237-1247.
24. Ohkanda, J.; Knowles, D.B.; Blaskovich, M.A.; Sebti, S.; Hamilton, A.D. Inhibitors of protein farnesyltransferase as novel anticancer agents. Curr. Topics Med. Chem., 2002, 2, 303-323.
25. Furfine, E.S.; Leban, J.J.; Landavazo, A.; Moomaw, J.F.; Casey, P.J. Protein farnesyltransferase: kinetics of farnesyl pyrophosphate binding and product release. Biochemistry, 1995, 34, 6857-6862.
26. Hightower, K.E.; Huang, C.C.; Casey, P.J.; Fierke, C.A. H-Ras peptide and protein substrates bind protein farnesyltransferase as an ionized thiolate. Biochemistry, 1998, 37, 15555-15562. (Pubitemid 28516020)
27. Sousa, S.F.; Fernandes, P.A.; Ramos, M.J. Farnesyltransferase: Theoretical studies on peptide substrate entrance thiol or thiolate coordination?. J. Mol. Struct. (Theochem), 2005, 729, 125-129. (Pubitemid 41247982)
28. Saderholm, M.J.; Hightower, K.E.; Fierke, C.A. Role of metals in the reaction catalyzed by protein farnesyltransferase. Biochemistry, 2000, 39, 12398-12405.
29. Long, S.B.; Hancock, P.J.; Kral, A.M.; Hellinga, H.W.; Beese, L.S. The crystal structure of human protein farnesyltransferase reveals the basis for inhibition by CaaX tetrapeptides and their mimetics. Proc. Natl. Acad. Sci. USA, 2001, 98, 12948-12953. (Pubitemid 33051300)
30. Strickland, C.L.; Windsor, W.T.; Syto, R.; Wang, L.; Bond, R.; Wu, Z.; Schwartz, J.; Le, H.V.; Beese, L.S.; Weber, P.C. Crystal structure of farnesyl protein transferase complexed with a CaaX peptide and farnesyl diphosphate analogue. Biochemistry, 1998, 37, 16601-16611. (Pubitemid 28543919)
31. Long, S.B.; Casey, P.J.; Beese, L.S. The basis for K-Ras4B binding specificity to protein farnesyltransferase revealed by 2 Å resolution ternary complex structures. Struct. Fold. Des., 2000, 8, 209-222. (Pubitemid 30097366)
32. Long, S.B.; Casey, P.J.; Beese, L.S. Reaction path of protein farnesyltransferase at atomic resolution. Nature, 2002, 419, 645-650.
33. Pickett, J.S.; Bowers, K.E.; Hartman, H.L.; Fu, H.W.; Embry, A.C.; Casey, P.J.; Fierke, C.A. Kinetic studies of protein farnesyltransferase mutants establish active substrate conformation. Biochemistry, 2003, 42, 9741-9748. (Pubitemid 36993147)
34. Sousa, S.F.; Fernandes, P.A.; Ramos, M.J. Enzyme flexibility and the catalytic mechanism of farnesyltransferase: Targeting the relation. J. Phys. Chem. B, 2008, 112, 8681-8691.
35. Olepu, S.; Suryadevara, P.M.; Rivas, K.; Yokoyama, K.; Verlinde, C.L.M.J.; Chakrabarti, D.; Van Voorhis, W.C.; Gelb, M.H. 2-Oxotetrahydro- 1,8-naphthyridines as selective inhibitors of malarial protein farnesyltransferase and as anti-malarials. Bioorg. Med. Chem. Lett., 2008, 18, 494-497.
36. Bos, J.L. Ras oncogenes in human cancer: A review. Cancer Res., 1989, 49, 4682-4689. (Pubitemid 19213607)
37. Almoguera, C.; Shibata, D.; Forrester, K.; Martin, J.; Arnheim, N.; Perucho, M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell, 1988, 53, 549-554.
38. Rodenhuis, S.; Slebos, R.J.; Boot, A.J.; Evers, S.G.; Mooi, W.J.; Wagenaar, S.S.; Van Bodegom, P.C.; Bos, J.L. Incidence and possible clinical significance of K-rai oncogene activation in adenocarcinoma of the human lung. Cancer Res., 1988, 48, 5738-5741.
39. Bos, J.L.; Fearon, E.R.; Hamilton, S.R.; Verlaan-de Vries, M.; Van Boom, J.H.; Van der Eb, A.J.; Vogelstein, B. Prevalence of ras gene mutations in human colorectal cancer. Nature, 1987, 327, 293-297. (Pubitemid 17075079)
40. Vogelstein, B.; Fearon, E.R.; Hamilton, A.D.; Kern, S.E.; Preisinger, A.C.; Leppert, M.; Nakamura, Y.; White, R.; Smits, A.M.; Bos, J.L. Genetic alterations during colorectal-tumor development. New Engl. J. Med., 1988, 319, 525-532.
41. Available from: www.plasmodb.org. Accessed on 22/04/2013.
42. Chakrabarti, D.; Da Silva, T.; Barger, J.; Paquette, S.; Patel, H.; Patterson, S.; Allen, C.M. Protein farnesyltransferase and protein prenylation in Plasmodium falciparum. J. Biol. Chem., 2002, 277, 42066-42073. (Pubitemid 35257521)
43. Wiesner, J.; Kettler, K.; Sakowski, J.; Ortmann, R.; Katzin, A.M.; Kimura, E.A.; Silber, K.; Klebe, G.; Jomaa, H.; Schlitzer, M. Farnesyltransferase inhibitors inhibit the growth of malaria parasites in vitro and in vivo. Angew. Chem., Int. Ed. Engl., 2004, 43, 251-254. (Pubitemid 38082117)
44. Carrico, D.; Ohkanda, J.; Kendrick, H.; Yokoyama, K.; Blaskovich, M.A.; Bucher, C.J.; Buckner, F.S.; Van Voorhis, W.C.; Chakrabarti, D.; Croft, S.L.; Gelb, M.H.; Sebti, S.M.; Hamilton, A.D. In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability. Bioorg. Med. Chem., 2004, 12, 6517-6526. (Pubitemid 39535174)
45. Glenn, M.P.; Chang, S.Y.; Hucke, O.; Verlinde, C.L.; Rivas, K.; Horney, C.; Yokoyama, K.; Buckner, F.S.; Pendyala, P.R.; Chakrabarti, D.; Gelb, M.; Van Voorhis, W.C.; Sebti, S.M.; Hamilton, A.D. Structurally simple farnesyltransferase inhibitors arrest the growth of malaria parasites. Angew. Chem., Int. Ed. Engl., 2005, 44, 4903-4906. (Pubitemid 41138675)
46. Ryckebusch, A.; Gilleron, P.; Millet, R.; Houssin, R.; Lemoine, A.; Pommery, N.; Grellier, P.; Sergheraert, C.; Henichart, J.P. Novel N-(4-piperidinyl)benzamide antimalarials with mammalian protein farnesyltransferase inhibitory activity. Chem. Pharm. Bull., 2005, 53, 1324-1326. (Pubitemid 41425631)
47. Kettler, K.; Wiesner, J.; Silber, K.; Haebel, P.; Ortmann, R.; Sattler, I.; Dahse, H.M.; Jomaa, H.; Klebe, G.; Schlitzer, M. Non-thiol farnesyltransferase inhibitors: N-(4-aminoacylamino-3-benzoylphenyl)- 3-5-(4-nitrophenyl)-2 furylacrylic acid amides and their antimalarial activity. Eur. J. Med. Chem., 2005, 40, 93-101. (Pubitemid 40092382)
48. Glenn, M.P.; Chang, S.Y.; Horney, C.; Rivas, K.; Yokoyama, K.; Pusateri, E.E.; Fletcher, S.; Cummings, C.G.; Buckner, F.S.; Pendyala, P.R.; Chakrabarti, D.; Sebti, S.M.; Gelb, M.; Van Voorhis, W.C.; Hamilton, A.D. Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites. J. Med. Chem., 2006, 49, 5710-5727. (Pubitemid 44423709)
49. Nallan, L.; Bauer, K.D.; Bendale, P.; Rivas, K.; Yokoyama, K.; Horney, C.P.; Pendyala, P.R.; Floyd, D.; Lombardo, L.J.; Williams, D.K.; Hamilton, A.; Sebti, S.; Windsor, W.T.; Weber, P.C.; Buckner, F.S.; Chakrabarti, D.; Gelb, M.H.; Van Voorhis, W.C. Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J. Med. Chem., 2005, 48, 3704-3713. (Pubitemid 40776846)
50. Gelb, M.H.; Brunsveld, L.; Hrycyna, C.A.; Michaelis, S.; Tamanoi, F.; Van Voorhis, W.C.; Waldmann, H. Therapeutic intervention based on protein prenylation and associated modifications. Nat. Chem. Biol., 2006, 2, 518-526.
51. Eastman, R.T.; Buckner, F.S.; Yokoyama, K.; Gelb, M.H.; Van Voorhis, W.C. Thematic review series: lipid posttranslational modifications. Fighting parasitic disease by blocking protein farnesylation. J. Lipid Res., 2006, 47, 233-240.
52. Kim, H.K.; Lee, J.Y.; Bae, E.J.; Oh, P.S.; Park, W.I.; Lee, D.S.; Kim, J.I.; Lee, H.J. Hutchinson-Gilford progeria syndrome with G608G LMNA mutation. J. Korean Med. Sci., 2011, 26, 1642- 1645.
53. Marji, J.; O'Donoghue, S.I.; McClintock, D.; Satagopam, V.P.; Schneider, R.; Ratner, D.; Worman, H.J.; Gordon, L.B.; Djabali, K. Defective Lamin A-Rb signaling in Hutchinson-Gilford progeria syndrome and reversal by farnesyltransferase inhibition. PLoS ONE, 2010, 5, e11132 (1-14).
54. Parreno, J.; Cruz, A.V. Accelerated aging in patients with Hutchinson-Gilford progeria syndrome: Clinical signs, molecular causes, treatments, and insights into the aging process. UBC Med. J., 2011, 3, 8-12.
55. Sebti, S.M.; Hamilton, A.D. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: Lessons from mechanism and bench-to-bedside translational studies. Oncogene, 2000, 19, 6584-6593. (Pubitemid 32197696)
56. Brown, M.S.; Goldstein, J.L.; Paris, K.J.; Burnier, J.P.; Marsters, J.C. Tetrapeptide inhibitors of protein farnesyltransferase: Aminoterminal substitution in phenylalanine-containing tetrapeptides restores farnesylation. Proc. Natl. Acad. Sci. USA, 1992, 89, 8313- 8316.
57. Graham, S.L.; de Solms, S.J.; Giuliani, E.A.; Kohl, N.E.; Mosser, S.D.; Oliff, A.I.; Pompliano, D.L.; Rands, E.; Breslin, M.J.; Deana, A.A.; Garsky, V.M.; Scholz, T.H.; Gibbs, J.B.; Smith, R.L. Pseudopeptide inhibitors of ras farnesyl-protein transferase. J. Med. Chem., 1994, 37, 725-732. (Pubitemid 24123467)
58. Leftheris, K.; Kline, T.; Natarajan, S.; DeVirgilio, M.K.; Cho, Y.H.; Pluscec, J.; Ricca, C.; Robinson, S.; Seizinger, B.R.; Manne, V.; Meyers, C.A. Peptide based p21 ras farnesyl transferase inhibitors: Systematic modification of the tetrapeptide CA1A2X motif. Bioorg. Med. Chem. Lett., 1994, 4, 887-892.
59. Dinsmore, C.J., Bell, I.M., Inhibitors of farnesyltransferase and geranylgeranyltransferase-I for antitumor therapy: Substrate-based design, conformational constraint and biological activity, Curr. Topics Med. Chem., 2003, 3, 1075-1093.
60. Goldstein, J.L.; Brown, M.S.; Stradley, S.J.; Reiss Y.; Gierasch, L.M. Nonfarnesylated tetrapeptide inhibitors of protein farnesyltransferase. J. Biol. Chem., 1991, 266, 15575-15578. (Pubitemid 21907690)
61. Nigam, M.; Seong, C.M.; Qian, Y.; Hamilton, A.D.; Sebtim, S.M. Potent inhibition of human tumor p21ras farnesyltransferase by A1A2-lacking p2ras CA1A2X peptidomimetics. J. Biol. Chem., 1993, 268, 20695-20698. (Pubitemid 23292229)
62. Reiss, Y.; Stradley, S.J.; Gierasch, L.M.; Brown, M.S.; Goldstein, J.L. Sequence requirement for peptide recognition by rat brain p2lras protein farnesyltransferase. Proc. Natl. Acad. Sci. USA, 1991, 88, 732-736. (Pubitemid 21916097)
63. Agrawal, A.G.; Somani, R.R. Farnesyltransferase inhibitor in cancer treatment, Current cancer treatment - Novel beyond conventional approaches; Ozdemir, O. Ed.; InTech Europe, Rijeka, Croatia. 2011; pp. 150-172.
64. Duque, G.; Vidal, C.; Rivas, D. Protein isoprenylation regulates osteogenic differentiation of mesenchymal stem cells: effect of alendronate, and farnesyl and geranylgeranyl transferase inhibitors. Br. J. Pharmacol., 2011, 162, 1109-1118.
65. Symons, M. The Rac and Rho pathways as a source of drug targets for Ras-mediated malignancies. Curr. Opin. Biotechnol., 1995, 6, 668-774.
66. Gibbs, J.B. Ras C-terminal processing enzymes-new drug targets?. Cell, 1991, 65, 1-4. (Pubitemid 121001207)
67. Moores, S.L.; Schaber, M.D.; Mosser, S.D.; Rands, E.; O'Hara, M.B.; Garsky, V.M.; Marshall, M.S.; Pompliano, D.L.; Gibbs, J.B. Sequence dependence of protein isoprenylation. J. Biol. Chem., 1991, 266, 14603-14610. (Pubitemid 21907546)
68. Wasko, B.M.; Dudakovic, A.; Hohl, R.J. Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate. J. Pharmacol. Exp. Ther., 2011, 337, 540-546.
69. Appels, N.M.G.M.; Bolijn, M.J.; Chan, K.; Stephens, T.C.; Hoctin- Boes, G.; Middleton, M.; Beijnen, J.H.; de Bono, J.S.; Harris, A.L.; Schellens, J.H.M. Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer. Br. J. Cancer, 2008, 98, 1951-1958. (Pubitemid 351821567)
70. Casey, P.J.; Seabra, M.C. Protein prenyltransferases. J. Biol. Chem., 1996, 271, 5289-5292. (Pubitemid 26083855)
71. Lerner, E.C.; Qiani, Y.; Blaskovich, M.A.; Fossum, R.D.; Vogt, A.; Sun, J.; Cox, A.D.; Der, C.J.; Hamilton, A.D.; Sebti, S.M. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic ras signaling by inducing cytoplasmic accumulation of inactive Ras- Raf complexes. J. Biol. Chem., 1995, 270, 26802-26806. (Pubitemid 3007240)
72. McGuire, T.; Qian, Y.; Hamilton, A.D.; Sebti, S.M. Platelet derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation and not farnesylation. J. Biol. Chem., 1996, 271, 27402-27407. (Pubitemid 26367297)
73. Vogt, A.; Qian, Y.; Hamilton, A.D.; Sebti, S.M. Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts. Oncogene, 1996, 13, 1991-1999. (Pubitemid 26397459)
74. Vogt, A.; Sun, J.; Qian, Y.; Hamilton, A.D.; Sebti, S.M. The geranylgeranyltransferase I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21WAF/CIP/SDII in a-p53 independent manner. J. Biol. Chem., 1997, 272, 27224-27229. (Pubitemid 27452683)
75. Sun, J.; Blaskovich, M.A.; Knowles, D.; Qian, Y.; Ohkanda, J.; Bailey, R.D.; Hamilton, A.D.; Sebti, S.M. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, taxol, and gemcitabine. Cancer Res., 1999, 59, 4919-4926. (Pubitemid 29472897)
76. Garcia, A.M.; Rowell, C.; Ackerman, K.; Kowalczyk, J.J.; Lewis, M.D. Peptidomimetic inhibitors of Ras farnesylation and function in whole cells. J. Biol Chem., 1993, 268, 18415-18418. (Pubitemid 23273764)
77. Vogt, A.; Qian, Y.; Blaskovich, M.A.; Fossum, R.D.; Hamilton, A.D.; Sebti, S.M. A non-peptide mimetic of Ras-CAAX: Selective inhibition of farnesyltransferase and ras processing. J. Biol. Chem., 1995, 270, 660-664.
78. Miguel, K.; Pradines, A.; Sun, J.; Hamilton, A.D.; Sebti, S.M.; Favre, G. GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells. Cancer Res., 1997, 57, 1846-1850. (Pubitemid 27209708)
79. Sun, J.; Qian, Y.; Hamilton, A.D.; Sebti, S.M. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene, 1998, 16, 1467-1473. (Pubitemid 28151853)
80. Kohl, N.E.; Wilson, F.R.; Mosser, S.D.; Giuliani, E.; deSolms, S.J.; Conner, M.W.; Anthony, N.J.; Holtz, W.J.; Gomez, R.P.; Lee, T.J.; Smith, R.L.; Graham, S.L.; Hartman, G.; Gibbs, J.B.; Oliff, A. Protein farnesyltransferase inhibitors block the growth of rasdependent tumors in nude mice. Proc. Natl. Acad. Sci. USA, 1994, 91, 9141-9145.
81. Kohl, N.E.; Omer, C.A.; Conner, M.W.; Anthony, N.J.; Davide, J.P.; deSolms, S.J.; Guiliani, E.A.; Gomez, R.P.; Graham, S.L.; Hamilton, K.; Handt, L.K.; Hartman, G.D.; Koblan, K.S.; Kral, A.M.; Miller, P.J.; Mosser, S.O.; O'Neill, T.J.; Rands, E.; Schaber, M.D.; Gibb, J.B.; Oliff, A. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med., 1995, 1, 792-797.
82. Qiao, Y.; Gao, J.; Qiu, J.; Wu, L.; Guo, F.; Lo, K.K.W.; Li, D. Design, synthesis, and characterization of piperazinedione-based dual protein inhibitors for both farnesyltransferase and geranylgeranyltransferase- I. Eur. J. Med. Chem., 2011, 46, 2264-2273.
83. Bell, I.M. Inhibitors of protein prenylation 2000. Expert Opin. Ther. Pat., 2000, 10, 1813-1831.
84. Sebti, S.M.; Hamilton, A.D. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues. Expert Opin. Invest. Drugs, 2000, 9, 2767-2782.
85. Wang, L.; Wang, G.T.; Wang, X.; Tong, Y.; Sullivan, G.; Park, D.; Leonard, N.M.; Li, Q.; Cohen, J.; Gu, W.Z.; Zhang, H.; Bauch, J.L.; Jakob, C.G., Hutchins, C.W.; Stoll, V.S.; Marsh, K.; Rosenberg, S.H.; Sham, H.L.; Lin, N.H. Design, synthesis, and biological activity of 4-(4-cyano-2-arylbenzyloxy)-(3- methyl-3H-imidazol-4- yl)methylbenzonitriles as potent and selective farnesyltransferase inhibitors. J. Med. Chem., 2004, 47, 612-626. (Pubitemid 38129719)
86. Hunt, J.T.; Lee, V.G.; Leftheris, K.; Seizinger, B.; Carboni, J.; Mabus, J.; Ricca, C.; Yan, N.; Manne, V. Potent, cell active, nonthiol tetrapeptide inhibitors of farnesyltransferase. J. Med. Chem., 1996, 39, 353-358. (Pubitemid 26041449)
87. Bohm, M.; Mitsch, A.; Wißner, P.; Sattler, I.; Schlitzer, M. Exploration of novel aryl binding sites of farnesyltransferase using molecular modeling and benzophenone-based farnesyltransferase inhibitors. J. Med. Chem., 2001, 44, 3117-3124. (Pubitemid 32862342)
88. O'Connor, S.J.; Barr, K.J.; Wang, L.; Sorensen, B.K.; Tasker, A.S.; Sham, H.; Ng, A.C.; Cohen, J.; Devine, E.; Cherian, S.; Saeed, B.; Zhang, H.; Lee, J.Y.; Warner, R.; Tahir, S.; Kovar, P.; Ewing, P.; Alder, J.; Mitten, M.; Leal, J.; Marsh, K.; Bauch, J.; Hoffman, D.J.; Sebti, S.M.; Rosenberg, S.H. Second generation peptidomimetic inhibitors of protein farnesyltransferase demonstrating improved cellular potency and significant in vivo efficacy. J. Med. Chem., 1999, 42, 3701-3710. (Pubitemid 29445103)
89. Augeri, D.J.; Janowick, D.; Kalvin, D.; Sullivan, G.; Larsen, J.; Dickman, D.; Ding, H.; Cohen, J.; Lee, J.; Warner, R.; Kovar, P.; Cherian, S.; Saeed, B.; Zhang, H.; Tahir, S.; Ng, S.-C.; Sham, H.; Rosenberg, S.H. Potent and orally bioavailable noncysteinecontaining inhibitors of protein farnesyltransferase. Bioorg. Med. Chem. Lett., 1999, 9, 1069-1074. (Pubitemid 29204659)
90. Mitsch, A.; Wißner, P.; Silber, K.; Haebel, P.; Sattler, I.; Klebe, G.; Schlitzer, M. Non-thiol farnesyltransferase inhibitors: N-(4- tolylacetylamino-3-benzoylphenyl)-3-arylfurylacrylic acid amides. Bioorg. Med. Chem., 2004, 12, 4585-4600. (Pubitemid 39044350)
91. Schlitzera, M.; Sattler, I., Non-thiol farnesyltransferase inhibitors: the concept of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors. Eur. J. Med. Chem., 2000, 35, 721-726. (Pubitemid 30490279)
92. Schlitzer, M. Structure based design of benzophenone-based nonthiol farnesyltransferase inhibitors. Curr. Pharm. Des., 2002, 8, 1713-1722. (Pubitemid 34846198)
93. Patel, D.V.; Patel, M.M.; Robinson, S.S.; Gordon, E.M. Phenol based tripeptide inhibitors of ras farnesyl protein transferase. Bioorg. Med. Chem. Lett., 1994, 4, 1883-1888. (Pubitemid 24248797)
94. Schlitzer, M.; Sattler, I. Non-thiol farnesyltransferase inhibitors: the concept of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors. Eur. J. Med. Chem., 2000, 35, 721-726. (Pubitemid 30490279)
95. Tschantz, W.R.; Furfine, E.S.; Casey, P.J. Substrate binding is required for release of product from mammalian protein farnesyltransferase. J. Biol. Chem., 1997, 272, 9989-9993. (Pubitemid 27171671)
96. Belei, D.; Dumea, C.; Samson, A.; Farce, A.; Dubois, J.; Bîcu, E.; Ghinet, A. New farnesyltransferase inhibitors in the phenothiazine series. Bioorg. Med. Chem. Lett., 2012, 22, 4517-4522.
97. Baciu-Atudosie, L.; Ghinet, A.; Farce, A.; Dubois, J.; Belei, D,; Bicu, E. Synthesis and biological evaluation of new phenothiazine derivatives bearing a pyrazole unit as protein farnesyltransferase inhibitors. Bioorg. Med. Chem. Lett., 2012, 22, 6896-6902.
98. Abuhaie, C.M.; Ghinet, A.; Farce, A.; Dubois, J.; Gautret, P.; Rigo, B.; Belei, D.; Bîcu, E. Synthesis and biological evaluation of a new series of phenothiazine-containing protein farnesyltransferase inhibitors. Eur. J. Med. Chem., 2013, 59, 101-110.
99. Driggers, E.M.; Hale, S.P.; Lee, J.; Terrett, N.K. The exploration of macrocycles for drug discovery-an underexploited structural class. Nat. Rev. Drug Discov., 2008, 7, 608-624. (Pubitemid 351927725)
100. Chen, K.X.; Njoroge, F.G,: Arasappan, A.; Venkatraman, S.; Vibulbhan, B.; Yang, W.; Parekh, T.N.; Pichardo, J.; Prongay, A.; Cheng, K.C.; Butkiewicz, N.; Yao, N.; Madison, V.; Girijavallabhan, V. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from prolinebased macrocycles. J. Med. Chem., 2006, 49, 995-1005. (Pubitemid 43221647)
101. Bell, I. M.; Gallicchio, S.N.; Abrams, M.; Beese, L.S.; Beshore, D.C.; Bhimnathwala, H.; Bogusky, M.J.; Buser, C.A.; Culberson, J.C.; Davide, J.; Ellis-Hutchings, M.; Fernandes, C.; Gibbs, J.B.; Graham, S.L.; Hamilton, K.A.; Hartman, G.D.; Heimbrook, D.C.; Homnick, C.F.; Huber, H.E.; Huff, J.R.; Kassahun, K.; Koblan, K.S.; Kohl, N.E.; Lobell, R.B.; Lynch, J.J. Jr.; Robinson, R.; Rodrigues, A.D.; Taylor, J.S.; Walsh, E.S.; Williams, T.M.; Zartman, C.B. 3-Aminopyrrolidinones farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency. J. Med. Chem., 2002, 45, 2388-2409. (Pubitemid 34595210)
102. Moasser, M.M.; Sepp-Lorenzino, L.; Kohl, N.E.; Oliff, A.; Balog, A.; Su, D.S.; Danishefsky, S.J.; Rosen, N. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc. Natl. Acad. Sci. USA, 1998, 95, 1369-1374. (Pubitemid 28103398)
103. Marcus, A.I.; O'Brate, A.M.; Buey, R.M.; Zhou, J.; Thomas, S.; Khuri, F.R.; Andreu, J.M.; Diaz, F.; Giannakakou, P. Farnesyltransferase inhibitors reverse taxane resistance. Cancer Res., 2006, 66, 8838-8846. (Pubitemid 44449202)
104. Adjei, A.A.; Davis, J.N.; Bruzek, L.M.; Erlichman, C.; Kaufmann, S.H. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin. Cancer Res., 2001, 7, 1438-1445. (Pubitemid 32708700)
105. Siegel-Lakhai, W.S.; Crul, M.; Zhang, S.; Sparidans, R.W.; Pluim, D.; Howes, A.; Solanki, B.; Beijnen, J.H.; Schellens, J.H. Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra®, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumors. Br. J. Cancer, 2005, 93, 1222-1229. (Pubitemid 41679407)
106. Mackay, H.J.; Hoekstra, R.; Eskens, F.A.L.M.; Loos, W.J.; Crawford, D.; Voi, M.; Van Vreckem, A.; Evans, T.R.J.; Verweij, J. A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors. Clin. Cancer Res., 2004, 10, 2636-2644. (Pubitemid 38509136)
107. Doisneau-Sixou, S.F.; Cestac, P.; Faye, J.C.; Favre, G.; Sutherland, R.L. Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression. Int. J. Cancer, 2003, 106, 789-798. (Pubitemid 37006315)
108. Ellis, C.A.; Vos, M.D.; Wickline, M.; Riley, C.; Vallecorsa, T.; Telford, W.G.; Zujewski, J.; Clark, G.J. Tamoxifen and the farnesyl transferase inhibitor FTI-2777 synergise to inhibit growth in estrogen receptor positive breast tumor cell lines. Breast Cancer Res. Treat., 2003, 78, 59-67. (Pubitemid 36223018)
109. Dalenc, F.; Giamarchi, C.; Petit, M.; Poirot, M.; Favre, G.; Faye, J.C. Farnesyltransferase inhibitor R115,777 enhances tamoxifen inhibition of MCF-7 cell growth through estrogen receptor dependent and independent pathways. Breast Cancer Res., 2005, 7, R1159-R1167.
110. Russo, P.; Ottoboni, C.; Malacarne, D.; Crippa, A.; Riou, J.F.; O'Connor, P.M. Nonpeptidomimetic farnesyltransferase inhibitor RPR-115135 increases cytotoxicity of 5-fluorouracil: Role of p53. J. Pharmacol. Exp. Ther., 2002, 300, 220-226. (Pubitemid 34028531)
111. Russo, P.; Malacarne, D.; Falugi, C.; Trombino, S.; O'Connor, P.M. RPR-115135, a farnesyltransferase inhibitor, increases 5-FU- cytotoxicity in ten human colon cancer cell lines: role of p53. Int. J. Cancer, 2002, 100, 266-275. (Pubitemid 34728983)
112. Edamatsu, H.; Gau, C.L.; Nemoto, T.; Guo, L.; Tamanoi, F. Cdk inhibitors, roscovitine and olomoucine synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. Oncogene, 2000, 19, 3059-3068. (Pubitemid 30438462)
113. Brassard, D.L.; English, J.M.; Malkowski, M.; Kirschmeier, P.; Nagabhushan, T.L.; Bishop, W.R. Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras. Exp. Cell Res., 2002, 273, 138-146. (Pubitemid 34920664)
114. Patnaik, A.; Eckhardt, S.G.; Izbicka, E.; Rybak, M.; McCreery, H.; Davidson, K.; Hammond, L.; Mori, M.; Terada, K.; Bol, K.; Gentner, L.; Rowinsky, E. Administration of biologically and clinically relevant doses of the farnesyltransferase inhibitor R115777 and gemcitabine are feasible without pharmacokinetic (PK) interactions: A phase I and PK study (Proceedings of the 11th NCIEORTC Symposium on New Drugs in Cancer Therapy). Clin. Cancer Res., 2000, 6, 4517S (Abstract 257).
115. Patnaik, A.; Eckhardt, S.G.; Izbicka, E.; Tolcher, A.A.; Hammond, L.A.; Takimoto, C.H.; Schwartz, G.; McCreery, H.; Goetz, A.; Mori, M.; Terada, K.; Gentner, L.; Rybak, M.E.; Richards, H.; Zhang, S.; Rowinsky, E.K. A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies. Clin. Cancer Res., 2003, 9, 4761-7471.
116. Theodore, C.; Geoffrois, L.; Vermorken, J.B.; Caponigro, F.; Fiedler, W.; Chollet, P.; Ravaud, A.; Peters, G.J.; de Balincourt, C.; Lacombe, D.; Fumoleau, P. Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers. Eur. J. Cancer, 2005, 41, 1150-1157. (Pubitemid 40725573)
117. Brunner, T.B.; Gupta, A.K.; Shi, Y.; Hahn, S.M.; Muschel, R.J.; McKenna, W.G.; Bernhard, E.J. Farnesyltransferase inhibitors as radiation sensitizers. Int. J. Radiat. Biol., 2003, 79, 569-576. (Pubitemid 37311062)
118. Hahn, S.M.; Kiel, K.; Morrison, B.W.; Mohiuddin, M.; Delaney, T.F.; Smith, D.; Brown, R.; Pramanik, B.; Deutsch, P.; Bernhard, E.; Muschel, R.; McKenna, G. Phase I trial of farnesyl protein transferase inhibitor with L-788,123 in combination with radiotherapy. Clin. Cancer Res., 2000, 6, 4481S.
119. Zujewski, J.; Horak, I.D.; Bol, C.J.; Woestenborghs, R.; Bowden, C.; End, D.W.; Piotrovsky, V.K.; Chiao, J.; Belly, R.T.; Todd, A.; Kopp, W.C.; Kohler, D.R.; Chow, C.; Noone, M.; Hakim, F.T.; Larkin, G.; Gress, R.E.; Nussenblatt, R.B.; Kremer, A.B.; Cowan, K.H. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J. Clin. Oncol., 2000, 18, 927-941. (Pubitemid 30106625)
120. Venet, M.; End, D.; Angibaud, P. Farnesyl protein transferase inhibitor ZARNESTRATM R115777 - History of a discovery. Curr. Topics Med. Chem., 2003, 3, 1095-1102.
121. Li, Q.; Wang, G.T.; Li, T.; Gwaltney, S.L. II, Woods, K.W.; Claiborne, A.; Wang, X.; Gu, W.; Cohen, J.; Stoll, V.S.; Hutchins, C.; Frost, D.; Rosenberg, S.H.; Sham, H.L. Synthesis and activity of 1- aryl-10-imidazolyl methyl ethers as non-thiol farnesyltransferase inhibitors. Bioorg. Med. Chem. Lett., 2004, 14, 5371-5376. (Pubitemid 39348930)
122. Lin, N.H.; Wang, L.; Wang, X.; Wang, G.T.; Cohen, J.; Gu, W.Z.; Zhang, H.; Rosenberg, S.H.; Sham, H.L. Synthesis and biological evaluation of 1-benzyl-5-(3-biphenyl-2-yl-propyl)-1H-imidazole as novel farnesyltransferase inhibitor. Bioorg. Med. Chem. Lett., 2004, 14, 5057-5062. (Pubitemid 39233365)
123. Seifert, M.H.J.; Wolf, K.; Vitt, D. Virtual high-throughput in silico screening. Biosilico, 2003, 1, 143-149. (Pubitemid 40416767)
124. Manly, C.J.; Louise-May, S.; Hammer, J.D. The impact of informatics and computational chemistry on synthesis and screening. Drug Discov. Today, 2001, 6, 1101-1110. (Pubitemid 33042386)
125. Bleicher, K.H.; Böhm, H.J.; Müller, K.; Alanine, A.I. Hit and lead generation: beyond high-throughput screening. Nat. Rev. Drug Discov., 2003, 2, 369-378. (Pubitemid 37361707)
126. Moorthy, N.S.H.N.; Ramos, M.J.; Fernandes, P.A. Structural analysis of α-glucosidase inhibitors by validated QSAR models using topological and hydrophobicity based descriptors. Chemom. Intell. Lab Sys., 2011, 109, 101-112.
127. Moorthy, N.S.H.N.; Cerqueira, N.S.; Ramos, M.J.; Fernandes, P.A. QSAR analysis of 2-benzoxazolyl hydrazone derivatives for anticancer activity and its possible target prediction. Med. Chem. Res., 2012, 21, 133-144.
128. Sousa, S.F.; Fernandes, P.A.; Ramos, M.J. Unraveling the mechanism of the farnesyltransferase enzyme. J. Biol. Inorg. Chem., 2005, 10, 3-10. (Pubitemid 40174303)
129. Puntambekar, D.; Giridhar, R.; Yadav, M.R. 3D-QSAR studies of farnesyltransferase inhibitors: A comparative molecular field analysis approach. Bioorg. Med. Chem. Lett., 2006, 16, 1821-1827. (Pubitemid 43267358)
130. Vaidya, M.; Weigt, M.; Wiese, M. 3D-QSAR with the aid of pharmacophore search and docking-based alignments for farnesyltransferase inhibitors. Eur. J. Med. Chem., 2009, 44, 4070-4082.
131. Li, Q.; Li, T.; Woods, K.W.; Gu, W.Z.; Cohen, J.; Stoll, V.S.; Galicia, T.; Hutchins, C.; Frost, D.; Rosenberg, S.H.; Sham, H.L. Benzimidazolones and indoles as non-thiol farnesyltransferase inhibitors based on tipifarnib scaffold: synthesis and activity. Bioorg. Med. Chem. Lett., 2005, 15, 2918-2922. (Pubitemid 40732247)
132. Xie, A.; Odde, S.; Prasanna, S.; Doerksen, R.J. Imidazolecontaining farnesyltransferase inhibitors: 3D quantitative structure- activity relationships and molecular docking. J. Comput. Aided Mol. Des., 2009, 23, 431-448.
133. Wang, G.T.; Wang, X.; Wang, W.; Hasvold, L.A.; Sullivan, G.; Hutchins, C.W.; O'Conner, S.; Gentiles, R.; Sowin, T.; Cohen, J.; Gu, W.Z.; Zhang, H.; Rosenberg, S.H.; Sham, H.L. Design and synthesis of o-trifluoromethylbiphenyl substituted 2-aminonicotinonitriles as inhibitors of farnesyltransferase. Bioorg. Med. Chem. Lett., 2005, 15, 153-158. (Pubitemid 39575802)
134. Equbal, T.; Silakari, O.; Ravikumar, M. Three-dimensional quantitative structure-activity relationship (3D-QSAR) studies of various ether analogues of farnesyltransferase inhibitors. Internet Electronic J. Mol. Des., 2007, 6, 237-252. (Pubitemid 47511160)
135. Perez Gonzalez, M.; Caballero, J.; Tundidor-Camba, A.; Helguera, A.M.; Fernandez, M. Modeling of farnesyltransferase inhibition by some thiol and non-thiol peptidomimetic inhibitors using genetic neural networks and RDF approaches. Bioorg. Med. Chem., 2006, 14, 200-213. (Pubitemid 41635484)
136. Gasteiger, J.; Zupan, Neural networks in chemistry. J. Angew. Chem., Int. Ed. Engl., 1993, 32, 503-527.
137. Zupan, J.; Gasteiger, J. Neural networks in chemistry and drug design, Wiley-VCH, Weinheim, 1999.
138. Mitsch, A.; Bohm, M.; Wissner, P.; Sattler, I.; Schlitzer, M. Nonthiol farnesyltransferase inhibitors: utilization of an aryl binding site by 5-arylacryloylaminobenzophenones. Bioorg. Med. Chem., 2002, 10, 2657-2662. (Pubitemid 34626228)
139. Sakowski, J.; Sattler, I.; Schlitzer, M. Non-thiol farnesyltransferase inhibitors: N-(4-Acylamino-3-benzoylphenyl)-4-nitrocinnamic acid amides. Bioorg. Med. Chem., 2002, 10, 233-239. (Pubitemid 33121249)
140. Equbal, T.; Silakari, O.; Rambabu. G.; Ravikumar, M. Pharmacophore mapping of diverse classes of farnesyltransferase inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 1594-1600.
141. Tanaka, R.; Rubio, A.; Harn, N.K.; Gernert, D.; Grese, T.A.; Eishima, J.; Hara, M.; Yoda, N.; Ohashi, R.; Kuwabara, T.; Soga, S.; Akinaga, S.; Nara S.; Kand, Y. Design and synthesis of piperidine farnesyltransferase inhibitors with reduced glucuronidation potential. Bioorg. Med. Chem., 2007, 15, 1363-1382. (Pubitemid 46038130)
142. Asoh, K.; Kohchi, M.; Hyoudoh, I.; Ohtsuka, T.; Masubuchi, M.; Kawasaki, K.; Ebiike, H.; Shiratori, Y.; Fukami, T.A.; Kondoh, O.; Tsukaguchi, T.; Ishii, N.; Aoki, Y.; Shimma, N.; Sakaitani, M. Synthesis and structure-activity relationships of novel benzofuran farnesyltransferase inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 1753-1757.
143. Moorthy, N.S.H.N.; Sousa, S.F.; Ramos, M.J.; Fernandes, P.A. Structural feature study of benzofuran derivatives as farnesyltransferase inhibitors. J. Enz. Inhibit. Med. Chem., 2011, 26, 777-791.
144. End, D.W.; Smets, G.; Todd, A.V. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res., 2001, 61, 131-137. (Pubitemid 32095710)
145. Cox, A.D.; Der, C.J. Farnesyltransferase inhibitors: promises and realities. Curr. Opin. Pharmacol., 2002, 2, 388-393. (Pubitemid 34830969)
146. Silva, C.H.T.P.; Silva, V.B.; Resende, J.; Rodrigues, P.F.; Bononi, F.C.; Benevenuto, C.G.; Taft, C.A. Computer-aided drug design and ADMET predictions for identification and evaluation of novel potential farnesyltransferase inhibitors in cancer therapy. J. Mol. Graph. Model., 2010, 28, 513-523.
147. Ganguly, A.K.; Doll, R.J.; Girijavallabhan, V.M. Farnesyl protein transferase inhibition: A novel approach to anti-tumor therapy. The discovery and development of SCH 66336. Curr. Med. Chem., 2001, 8, 1419-1436. (Pubitemid 32894008)
148. Njoroge, F.G.; Vibulbhan, B.; Pinto, P.; Strickland, C.L.; Bishop, W.R.; Kirschmeir, P.; Girijavallabhan, V.; Ganguly, A.K. Trihalobenzocycloheptapyridine analogues of SCH 66336 as potent inhibitors of farnesyl protein transferase. Bioorg. Med. Chem., 2003, 11, 139-143. (Pubitemid 35430130)
149. Polley, M.J.; Winkler, D.A.; Burden, F.R. Broad-based quantitative structure-activity relationship modeling of potency and selectivity of farnesyltransferase inhibitors using a Bayesian regularized neural network. J. Med. Chem., 2004, 47, 6230-6238. (Pubitemid 39587247)
150. Fernandez, M.; Tundidor-Camba, A.; Caballero, J.M. 2D autocorrelation modeling of the activity of trihalobenzocycloheptapyridine analogues as farnesyl protein transferase inhibitors. Mol. Simulat., 2005, 31, 575-584. (Pubitemid 41119926)
151. Strickland, C.L.; Weber, P.T.; Windsor, W.T.; Wu, Z.; Le, H.V.; Albanese, M.M.; Alvarez, C.S.; Cesarz, D.; del Rosario, J.; Deskus, J.; Mallams, A.K.; Njoroge, F.G.; Piwinski, J.J.; Remiszewski, S.; Rossman, R.R.; Taveras, A.G.; Vibulbhan, B.V.; Doll, R.J.; Girijavallabhan, V.M.; Ganguly, A.K. Tricyclic farnesyl protein transferase inhibitors: Crystallographic and calorimetric studies of structure- activity relationships. J. Med. Chem., 1999, 42, 2125-2135. (Pubitemid 29284232)
152. Kwon, B M.; Lee, S.H.,; Cho, Y.K.; Bok, S.H.; So, S.H.; Youn, M.R.; Chang, S.I. Synthesis and biological activity of cinnamaldehyde as angiogenesis inhibitors. Bioorg. Med. Chem. Lett., 1997, 7, 2473-2476.
153. Sung, N.D.; Cho, Y.K.; Kwon, B.M.; Hyun, K.H.; Kim, C.K. 3D QSAR studies on cinnamaldehyde analogues as farnesyl protein transferase inhibitors. Arch. Pharm. Res., 2004, 27, 1001-1008.
154. Soung, M.G.; Kim, J.H.; Kwon, B.M.; Sung, N.D. Synthesis and ligand based 3D-QSAR of 2,3-bis-benzylidenesuccinaldehyde derivatives as new class potent FPTase inhibitor, and prediction of active molecules. Bull. Korean Chem. Soc., 2010, 31, 1355-1360.
155. Burden, F.R.; Winkler, D.A. Robust QSAR models using Bayesian regularized neural networks. J. Med. Chem., 1999, 42, 3183-3187. (Pubitemid 29384055)
156. Burden, F.R. Using artificial neural networks to predict biological activity from simple molecular structure considerations. Quant. Struct.-Act. Relat., 1996, 15, 7-11. (Pubitemid 26072214)
157. Bishop, W.R.; Bond, R.; Petrin, J.; Wang, L.; Patton, R.; Doll, R.; Njoroge, G.; Catino, J.; Schwartz, J.; Windsor, W.; Sayto, R.; Schwartz, J.; Carr, D.; James, L.; Kirschmeier, P. Novel tricyclic inhibitors of farnesyl protein transferase. J. Biol. Chem., 1995, 270, 30611-30618.
158. Mallams, A.K.; Njoroge, F.G.; Doll, R.J.; Snow, M.E.; Kaminski, J.J.; Rossman, R.; Vibulbhan, B.; Bishop, W.R.; Kirschmeier, P.; Liu, M.; Bryant, M.S.; Alvarez, C.; Carr, D.; James, L.; King, I.; Li, Z.; Lin, C.-C.; Nardo, J.; Petrin, J.; Remiszewski, S.; Taveras, A.; Wang, S.; Wong, J.; Catino, J.; Girijavallabhan, V.; Ganguly, A.K. Antitumor 8- chlorobenzocycloheptapyridines: A new class of selective, nonpeptidic, nonsulfhydryl inhibitors of ras farnesylation. Bioorg. Med. Chem., 1997, 5, 93-99. (Pubitemid 27065353)
159. Njoroge, F.G.; Doll, R.J.; Vibulbhan, B.; Alvarez, C.; Bishop, W.R.; Petrin, J.; Kirschmeier, P.; Carruthers, N.I.; Wong, J.K.; Albanese, M.M.; Piwinski, J.J.; Catino, J.; Girijavallabhan, V.; Ganguly, A.K. Discovery of novel nonpeptide tricyclic inhibitors of ras farnesylation. Bioorg. Med. Chem., 1997, 5, 101-114.
160. Rane, D.F.; Pike, R.E.; Puar, M.S.; Wright, J.J.; McPhail, A.T. A novel synthesis of cis-1-6-chloro-3-(2-chloro-3-thienyl)- methoxy-2, 3-dihydrobenzobthien-2-ylmethyl-1H-imidazole. A new class of azole antifungal agents. Tetrahedron, 1988, 44, 2397- 2402.
161. Kaminski, J.J.; Rane, D.F.; Snow, M.E.; Weber, L.; Rothofsky, M.L.; Anderson, S.D.; Lin, S.L. Identification of novel farnesyl protein transferase inhibitors using three-dimensional database searching methods. J. Med. Chem., 1997, 40, 4103-4112. (Pubitemid 28008404)
162. Giraud, E.; Luttmann, C.; Lavelle, F.; Riou, J.F.; Mailliet, P.; Laoui, A. Multivariate data analysis using D-optimal designs, partial least squares, and response surface modeling: A directional approach for the analysis of farnesyltransferase inhibitors. J. Med. Chem., 2000, 43, 1807-1816. (Pubitemid 30305013)
163. Xie, A.; Clark, S.R.; Prasanna, S.; Doerksen, R.J. Threedimensional quantitative structure-farnesyltransferase inhibition analysis for some diaminobenzophenones. J. Enz. Inhib. Med. Chem., 2009, 24, 1220-1228.
164. Gaurav, A.; Gautam, V.; Singh, R. Exploring the structure activity relationships of imidazole containing tetrahydrobenzodiazepines as farnesyltransferase inhibitors: A QSAR study. Lett. Drug Des. Discov., 2011, 8, 506-515.
165. Shayanfar, A.; Ghasemi, S.; Soltani, S.; Asadpour-Zeynali, K.; Doerksen, R.J.; Jouyban, A. Quantitative structure-activity relationships of imidazole-containing farnesyltransferase inhibitors using different chemometric methods. Med. Chem., 2013, 9, 434-448.
166. Lethu, S.; Ginisty, M.; Bosc, D.; Dubois, J. Discovery of a new class of protein farnesyltransferase inhibitors in the arylthiophene series. J. Med. Chem., 2009, 52, 6205-6208.
167. Moorthy, N.S.H.N.; Sousa, S.F.; Ramos, M.J.; Fernandes, P.A. In silico-based structural analysis of arylthiophene derivatives for FTase inhibitory activity, hERG, and other toxic effects. J. Biomol. Screen., 2011, 16, 1037-1046.
168. Chaurasia, S.; Srivastava, A.K.; Nath, A.; Srivastava, M.K.; Pandey, A. Quantitative structure activity relationship studies on a series of tetrahydroquinoline-based farnesyltransferase inhibitors. Oxid. Commun., 2007, 30, 778-787.
169. Bendale, P.; Olepu, S.; Suryadevara, P.K.; Bulbule, V.; Rivas, K.; Nallan, L.; Smart, B.; Yokoyama, K.; Ankala, S.; Pendyala, P.R.; Floyd, D.; Lombardo, L.J.; Williams, D.K.; Buckner, F.S.; Chakrabarti, D.; Verlinde, C.L.; Van Voorhis, W.C.; Gelb, M.H. Second generation tetrahydroquinoline-based protein farnesyltransferase inhibitors as antimalarials. J. Med. Chem., 2007, 50, 4585-4605. (Pubitemid 47463234)
170. Wiesner, J.; Mitsch, A.; Wißner, P.; Jomaa, H.; Schlitzer, M. Structure- activity relationships of novel anti-malarial agents. Part 2: cinnamic acid derivatives. Bioorg. Med. Chem. Lett., 2001, 11, 423- 424. (Pubitemid 32115862)
171. Wiesner, J.; Kettler, K.; Jomaa, H.; Schlitzer, M. Structure-activity relationships of novel anti-malarial agents. Part 3: N-(4-acylamino- 3-benzoylphenyl)-4-propoxycinnamic acid amides. Bioorg. Med. Chem. Lett., 2002, 12, 543-545. (Pubitemid 34158890)
172. Wiesner, J.; Mitsch, A.; Wißner, P.; Kramer, O.; Jomaa, H.; Schlitzer, M. Structure-activity relationships of novel anti-malarial agents. Part 4: N-(3-benzoyl-4-tolylacetylaminophenyl)-3-(5-aryl- 2-furyl)acrylic acid amides. Bioorg. Med. Chem. Lett., 2002, 12, 2681-2683. (Pubitemid 35247618)
173. Wiesner, J.; Kettler, K.; Sakowski, J.; Ortmann, R.; Jomaa, H.; Schlitzer, M. Structure-activity relationships of novel anti-malarial agents: part 5. N-(4-acylamino-3-benzoylphenyl)-5-(4-nitrophenyl)- 2-furylacrylic acid amides. Bioorg. Med. Chem. Lett., 2003, 13, 361-363. (Pubitemid 36259692)
174. Wiesner, J.; Fucik, K.; Kettler, K.; Sakowski, J.; Ortmann, R.; Jomaa, H.; Schlitzer, M. Structure-activity relationships of novel anti-malarial agents. Part 6: N-(4-arylpropionylamino-3-benzoylphenyl)- 5-(4-nitrophenyl)-2- furylacrylic acid amides. Bioorg. Med. Chem. Lett., 2003, 13, 1539-1541. (Pubitemid 36428555)
175. Wiesner, J.; Mitsch, A.; Jomaa, H.; Schlitzer, M. Structure-activity relationships of novel anti-malarial agents. Part 7: N-(3-benzoyl-4- tolylacetylaminophenyl)-3-(5-aryl-2-furyl)acrylic acid amides with polar moieties. Bioorg. Med. Chem. Lett., 2003, 13, 2159-2161. (Pubitemid 36694296)
176. Cormanich, R.A.; Freitas, M.P.; Rittner, R. 2D chemical drawings correlate to bioactivities: MIA-QSAR modelling of antimalarial activities of 2,5-diaminobenzophenone derivatives. J. Braz. Chem. Soc., 2011, 22, 637-642.
177. Deeb, O.; Alfalah, S.; Freitas, M.P.; Cunha, E.F.F.; Ramalho, T.C. Exploring MIA-QSARs for farnesyltransferase inhibitory effect of antimalarial compounds refined by docking simulations. J. Biophys. Chem., 2012, 3, 58-71.
178. Schmitz, F.J.; Bloor, S.J. Xesto- and halenaquinone derivatives from a sponge, Adocia sp., from Truk lagoon. J. Org. Chem., 1988, 53, 3922-3925.
179. Cao, S.; Foster, C.; Brisson, M.; Lazo, J.S.; Kingston, D.G.I. Halenaquinone and xestoquinone derivatives, inhibitors of Cdc25B phosphatase from a Xestospongia sp. Bioorg. Med. Chem., 2005, 13, 999-1003. (Pubitemid 40164583)
180. Alvi, K.A.; Rodríguez, J.; Diaz, M.C.; Moretti, R.; Wilhelm, R.S.; Lee, R.H.; Slate, D. L.; Crews, P. Protein tyrosine kinase inhibitory properties of planar polycyclics obtained from the marine sponge Xestospongia cf. carbonaria and from total synthesis. J. Org. Chem., 1993, 58, 4871-4880. (Pubitemid 23302428)
181. Kobayashi, J.; Hirase, T.; Shigemori, H.; Ishibashi, M.; Bae, M.-A.; Tsuji, T.; Sasaki, T. New pentacyclic compounds from the okinawan marine sponge Xestospongia sapra. J. Nat. Prod., 1992, 55, 994-998.
182. Kobayashi, M.; Shimizu, N.; Kyogoku, Y.; Kitagawa, I. Halenaquinol and halenaquinol sulphate, pentacyclic hydroquinones from the okinawan marine sponge Xestospongia sapra. Chem. Pharm. Bull., 1985, 33, 1305-1308.
183. Roll, D.M.; Scheuer, P.J.; Matsumoto, G.K.; Clardy, J. Halenaquinone, a pentacyclic polyketide from a marine sponge. J. Am. Chem. Soc., 1983, 105, 6177-6178.
184. Desoubzdanne, D.; Marcourt, L.; Raux, R.; Chevalley, S.; Dorin, D.; Doerig, C.; Valentin, A.; Ausseil, F.; Debitus, C. Alisiaquinones and alisiaquinol, dual inhibitors of Plasmodium falciparum enzyme targets from a New Caledonian deep water sponge. J. Nat. Prod., 2008, 71, 1189-1192.
185. Longeon, A.; Copp, B.R.; Roué, M.; Dubois, J.; Valentin, A.; Petek, S.; Debitus, C.; Bourguet-Kondracki, M.L. New bioactive halenaquinone derivatives from South Pacific marine sponges of the genus Xestospongia. Bioorg. Med. Chem., 2010, 18, 6006-6011.
186. Yonemoto, M.; Satoh, T.; Arakawa, H.; Suzuki-Takahashi, I.; Monden, Y.; Kodera, T.; Tanaka, K.; Aoyama, T.; Iwasawa, Y.; Kamei, T.; Nishimura, S.; Tomimoto, K. J-104,871, a novel farnesyltransferase inhibitor, blocks Ras farnesylation in vivo in a farnesyl pyrophosphate-competitive manner. Mol. Pharmacol., 1998, 54, 1-7. (Pubitemid 28337580)
187. Hardin, J.; MacLeod, S.; Grigorieva, I.; Chang, R.; Barlogie, B.; Xiao, H.; Epstein, J. Interleukin-6 prevents dexamethasone induced myeloma cell death. Blood, 1994, 84, 3063-3070. (Pubitemid 24328099)
188. Hilbert, D.M.; Kopf, M.; Mock, B.A.; Kohler, G.; Rudikoff, S. Interleukin 6 is essential for in vivo development of B lineage neoplasms. J. Exp. Med., 1995, 182, 243-248.
189. Frassanito, M.A.; Cusmai, A.; Piccoli, C.; Dammacco, F. Manumycin inhibits farnesyltransferase and induces apoptosis of drug-resistant interleukin 6-producing myeloma cells. Br. J. Haematol., 2002, 118, 157-165. (Pubitemid 34779532)
190. Kim, Y.S.; Kim, J.S.; Park, S.H.; Choi, S.U.; Lee, C.O.; Kim, S.K.; Kim, Y.K.; Kim, S.H.; Ryu, S.Y. Two cytotoxic sesquiterpene lactones from the leaves of Xanthium strumarium and their in vitro inhibitory activity on farnesyltransferase. Planta Med., 2003, 69, 375-377. (Pubitemid 36578008)
191. Ancuceanu, R.V.; Istudor, V. Pharmacologically active natural compounds for lung cancer. Altern. Med. Rev. 2004, 9, 402-419. (Pubitemid 40066714)
192. Nour, A.M.; Khalid, S.A.; Kaiser, M.; Brun, R.; Abdallah, W.E.; Schmidt, T.J. The antiprotozoal activity of sixteen asteraceae species native to Sudan and bioactivity-guided isolation of xanthanolides from Xanthium brasilicum. Planta Med., 2009, 75, 1363- 1368.
193. Ahmed, A.A.; Jakupovic, J.; Bohlmann, F.; Regaila, H.A.; Ahmed, A.M. Sesquiterpene lactones from Xanthium pungens. Phytochemistry, 1990, 29, 2211-2215.
194. Cumanda, J.; Marinoni, G.; de Bernardi, M.; Vidari, G.; Vita Finzi, P. New sesquiterpenes from Xanthium catharticum. J. Nat. Prod., 1991, 54, 460-465.
195. de Riscala, E.C.; Fortuna, M.A.; Catalan, C.A.N.; Diaz, J.G.; Herz, W. Xanthanolides and a bis-norxanthanolide from Xanthium cavanillesii. Phytochem., 1994, 35, 1588-1589. (Pubitemid 2067943)
196. Joshi, S.P.; Rojatkar, S.R.; Nagasampagi, B.A. Antimalarial activity of Xanthium strumarium Linn. J. Med. Aromat. Plant Sci., 1997, 19, 366-368.
197. Vasas, A.; Hohmann, J. Xanthane sesquiterpenoids: structure, synthesis and biological activity. Nat. Prod. Rep., 2011, 28, 824- 842.
198. Kuo, Y.H.; Lin, B.Y. A new dinorxanthane and chromanone from the root of Tithonia diversifolia. Chem. Pharm. Bull., 1999, 47, 428-429.
199. Matsuo, K.; Yokoe, H.; Shishido, K.; Shindo, M. Synthesis of diversifolide and structure revision. Tetrahedron Lett., 2008, 49, 4279-4281.
200. Kwon, B.M.; Lee, S.H.; Kim, M.J.; Kim, H.K.; Kim, H.M. Isolation of farnesyltransferase inhibitors from herbal medicines. Ann. N. Y. Acad. Sci., 1999, 886, 261-264. (Pubitemid 30042453)
201. Picman, A.K. Biological activities of sesquiterpene lactones. Biochem. Syst. Ecol., 1986, 14, 255-281.
202. Das, M.; Chaudhuri, T.; Goswami, S.K. Studies with black tea and its constituents on leukemic cells and cell lines. J. Exp. Clin. Cancer Res., 2002, 21, 563-568. (Pubitemid 36193806)
203. Manna, S.; Mukherjee, S.; Roy, A. Tea polyphenols can restrict benzoapyrene-induced lung carcinogenesis by altered expression of p53-associated genes and H-ras, c-myc and cyclin D1. J. Nutr. Biochem., 2009, 20, 337-349.
204. Balajee, R.; Dhana Rajan, M.S. Molecular docking and simulation studies of farnesyl transferase with the potential inhibitor Theflavin. J. Appl. Pharm. Sci., 2011, 1, 141-148.
205. Dalsgaard, P.W.; Petersen, B.O.; Duus, J.O.; Zidorn, C.; Frisvad, J.C.; Christophersen, C.; Larsen, T.O. Atlantinone A, a meroterpenoid produced by Penicillium ribeum and several cheese associated Penicillium species. Metabolites, 2012, 2, 214-220.
206. Shiomi, K.; Uchida, R.; Inokoshi, J.; Tanaka, H.; Iwai, Y.; Omura, S. Andrastins A-C, new protein farnesyltransferase inhibitors, produced by Penicillium sp. FO-3929. Tetrahedron Lett., 1996, 37, 1265-1268.
207. Omura, S.; Inokoshi, J.; Uchida, R.; Shiomi, K.; Masuma, R.; Kawakubo, T.; Tanakaf, H.; Iwai, Y.; Kosemurall, S.; Yamamurall, S. Andrastins A-C, new protein farnesyltransferase inhibitors produced by penicillium sp. FO-3929. I. Producing strain, fermentation, isolation, and biological activities. J. Antibiotics, 1996, 49, 414-417.
208. Houbraken, J.; Samson, R.A. Phylogeny of Penicillium and the segregation of Trichocomaceae into three families. Stud. Mycol., 2011, 70, 1-51.
209. Thutewohl, M.; Kissau, L.; Popkirova, B.; Karaguni, I.M.; Nowak, T.; Bate, M.; Kuhlmann, J.; Muller, O.; Waldmann, H. Identification of mono- and bisubstrate inhibitors of protein farnesyltransferase and inducers of apoptosis from a pepticinnamin E library. Bioorg. Med. Chem., 2003, 11, 2617-2626. (Pubitemid 36566622)
210. Sun, D. Highly stereoselective and efficient synthesis of the dopa analogue in pepticinnamin E via enantioselective hydrogenation of dehydroamino acids. Turk. J. Chem., 2010, 34, 181-186.
211. Leonard, D.M.; Schuber, K.R.; Poulter, C.J.; Eaton, S.R.; Sawyer, T.K.; Hodges, J.C.; Su T,-Z.; Scholten, J.D.; Gowan, R.; Sebold- Leopold, J.S.; Doherty, A.M. Structure-activity relationships of cysteine-lacking pentapeptide derivatives that inhibit ras farnesyltransferase. J. Med. Chem., 1997, 40, 192-200. (Pubitemid 27045075)
212. Waldmann, H.; Thutewohl, M. Ras-farnesyltransferase-inhibitors as promising anti-tumor drugs. Topics Curr. Chem., 2000, 211, 117-130.
213. Singh, S.B.; Jones, E.T.; Goetz, M.A.; Bills, G.F.; Nallin-Omstead, M.; Jenkins, R.G.; Lingham, R.B.; Silverman, K.C.; Gibbs, J.B. Fusidienol: A novel inhibitor of Ras farnesyl-protein transferase from Fusidiumgriseum. Tetrahedron Lett., 1994, 35, 4693-4696. (Pubitemid 24212596)
214. Singh, S.B.; Zink, D.L.; Liesch, J M.; Ball, R.G.; Goetz, M.A.; Bolessa, E.A.; Giacobbe, R.A.; Silverman, K.C.; Bills, G.F.; Pelaez, F.; Cascales, C.; Gibbs, J.B.; Lingham, R.B. Preussomerins and deoxypreussomerins: Novel inhibitors of ras farnesyl-protein transferase. J. Org. Chem., 1994, 59, 6296-6302. (Pubitemid 24351145)
215. Larsen, B.; Shah, D. Candida isolates of yeast produce a gliotoxinlike substance. Mycopathologia, 1991, 116, 203-208.
216. Van Der Pyl, D.; Inokoshi, J.; Shiomi, K.; Yang, H.; Takeshima, H.; Omura, S. Inhibition of farnesyl protein transferse by gliotoxin and acetylgliotoxin. J. Antibiotics, 1992, 45, 1802-1805. (Pubitemid 23015465)
217. Singh, S.B.; Zink, D.L.; Bills, G.F.; Jenkins, R.G.; Silverman, K.C.; Lingham, R.B. Cylindrol A: A novel inhibitor of ras farnesylprotein transferase from Cylindrocarpon lucidum. Tetrahed. Lett., 1995, 36, 4935-4938.
218. Liu, C.; Barbacid, M.; Bulgar, M.; Clark, J.M.; Crosswell, A.R.; Dean, L.; Doyle, T.W.; Fernandes, P.B.; Huang, S.; Manne, V.; Pirnik, D.M.; Wells, J.S.; Meyers, E. O'-Desmethoxystreptonigrin, A novel analog of streptonigrin. J. Antibiotics, 1992, 45, 454-457.
219. Nonomura, H. Key for classification and identification of 458 species of the streptomycetes included in ISP. J. Ferment. Technol., 1974, 52, 78-92.
220. Lingham, R.B.; Sheo, B. Singh, Farnesyl-protein transferase: A new paradigm for cancer chemotherapy, advances in discovery and development of natural product inhibitors. Stud. Nat. Prod. Chem., 2000, 24, 403-472.
221. Singh, S.B.; Zinc, D.L.; Liesch, J.M.; Goetz, M.A.; Jenkins, R.G.; Nallin-Omstead, M.; Silverman, K.C.; Bills, G.F.; Mosley, R.T.; Gibbs, J.B.; Albers- Schonberg, G.; Lingham, R.B. Isolation and structure of Chaetomelic acids A and B from Chaetomella acutiseta: Farnesyl pyrophosphate mimic inhibitors of ras farnesylprotein transferase. Tetrahedron 1993, 49, 5917-5926.
222. Bellesia, F.; Choi, S.R.; Felluga, F.; Fiscaletti, G.; Ghelfi, F.; Menziani, M.C.; Parsons, A.F.; Poulter, C.D.; Roncaglia, F.; Sabbatini, M.; Spinelli, D. Novel route to chaetomellic acid A and analogues: Serendipitous discovery of a more competent FTase inhibitor. Bioorg. Med. Chem., 2013, 21, 348-358.
223. Singh, S.B.; Liesch, J.M.; Lingham, R.B.; Silverman, K.C.; Sigmund, J.M.; Goetz, M.A. Structure, chemistry, and biology of actinoplanic acids: Potent inhibitors of Ras farnesyl-protein transferase. J. Org. Chem., 1995, 60, 7896-7901.
224. Gibbs, J.B.; Pompliano, D.L.; Mosser, S.D.; Rands, E.; Linghan, R.B.; Singh, S.B.; Scolnick, E.M.; Kohl, N.E. Selective-inhibition of farnesyl-protein transferase blocks ras processing. J. Biol. Chem., 1993, 268, 7617-7620. (Pubitemid 23120323)
225. Dbrah, T.T.; Kaneko, T.W.; Massefski, J.; Whipple, E.B. CP-225, 917 and CP-263, 114: Novel ras farnesylation inhibitors from an unidentified fungus. 2. Structure elucidation. J. Am. Chem. Soc., 1997, 119, 1594-1598. (Pubitemid 27145502)
226. Tomillero, A.; Moral, M.A. Gateways to clinical trials. Methods Find Exp. Clin. Pharmacol., 2010, 32, 599-620.
227. Caponigro, F. Farnesyltransferase inhibitors: A major breakthrough in anticancer therapy? Naples, 12 April 2002. Anticancer Drugs, 2002, 13, 891-897.
228. Caponigro, F.; Casale, M.; Bryce, J. Farnesyltransferase inhibitors in clinical development. Expert Opin. Invest. Drugs, 2003, 12, 943- 954.
229. Available from: http://clinicaltrials.gov/ct2/show/NCT00354146. A phase 2 study of farnesyl transferase inhibitor (R115777, Tipifarnib) in patients with refractory or relapsed acute myeloid leukemia. Accessed on 22-04-2013.
230. Reid, T.S.; Beese, L.S. Crystal structures of the anticancer clinical candidates R115777 (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity. Biochemistry, 2004, 43, 6877-6884. (Pubitemid 38720505)
231. Available from: http://www.progeriaresearch.org/first-everprogeria- treatment.html. Accessed on 25-04-2013.
232. Available from: http://clinicaltrials.gov/ct2/show/NCT00425607. Accessed on 25-04-2013.
233. Gordona, L.B.; Kleinmana, M.E.; Millerd, D.T.; Neubergg, D.S.; Giobbie-Hurderg, A.; Gerhard-Hermani, M.; Smootj, L.B.; Gordonc,k, C.M.; Clevelandm, R.; Snydern, B.D.; Fligorp, B.; Bishopq, W.R.; Statkevichq, P.; Regenr, A.; Sonisr, A.; Rileys, S.; Ploskis, C.; Correias, A.; Quinnt, N.; Ullrichv, N.J.; Nazariano, A.; Liangd, M.J.; Huhd, S.Y.; Schwartzmang, A.; Kieranx, M.W. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc. Natl. Acad. Sci. USA, 2012, 109, 16666-16671.
234. Bolchi, C.; Pallavicini, M.; Fumagalli, L.; Ferri, N.; Corsini, A.; Rusconi, C.; Valoti, E. New Ras CAAX mimetics: design, synthesis, antiproliferative activity, and RAS prenylation inhibition. Bioorg. Med. Chem. Lett., 2009, 19, 5500-5504.
235. Eskens, F.A.L.M. & Stoter, G., Verweij, J. Farnesyl transferase inhibitors: current developments and future perspectives. Cancer Treat. Rev., 2000, 26, 319-332.
236. Tsimberidou, A.M.; Chandhasin, C.; Kurzrock, R. Farnesyltransferase inhibitors: where are we now?. Expert Opin. Invest. Drugs, 2010, 19, 1569-1580.
237. Available from: www.ClinicalTrials.gov identifier NCT00383474. Phase I combination trial, the effect of combination treatment of tipifarnib and bortezomib in patients with advanced acute leukemias. Accessed on 22-04-2013.
238. Lancet, J.E.; Duong, V.H.; Winton, E.F.; Stuart, R.K.; Burton, M.; Zhang, S.; Cubitt, C.; Blaskovich, M.A.; Wright, J.J.; Sebti, S.; Sullivan, D.M. A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. Clin. Cancer Res., 2011, 17, 1140-1146.
239. Available from: http://clinicaltrialsfeeds.org/clinical-trials/results/ term=FTI. Accessed on 25-04-2013.
240. Available from: http://clinicaltrials.gov/ct2/show/NCT00038597. Phase II study of SCH66336, A farnesyltransferase inhibitor in chronic myelogenous leukemia (CML). Accessed on 22-04-2013.
241. Rakha, P.; Gupta, A.; Dhingra, G.; Nagpal, M. Hutchinson- Gilford progeria syndrome: A review. Der Pharmacia Sinica, 2011, 2, 110-117.
242. Peng, G.; Ren, Y.; Sun, X.; Zhou, J.; Li, D. Inhibition of farnesyltransferase reduces angiogenesis by interrupting endothelial cell migration. Biochem. Pharmacol., 2012, 83, 1374-1382.
243. Widemann, B.C.; Arceci, R.J.; Jayaprakash, N.; Fox, E.; Zannikos, P.; Goodspeed, W.; Goodwin, A.; Wright, J.J.; Blaney, S.M.; Adamson, P.C.; Balis, F.M. Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group. Pediatr. Blood Cancer, 2011, 56, 226-233.
244. Pellicano, F.; Copland, M.; Jorgensen, H.G.; Mountford, J.; Leber, B.; Holyoake, T.L. BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cbeta. Blood, 2009, 114, 4186-4196.
245. Balabanov, S.; Evans, C.A.; Abraham, S.A.; Pellicano, F.; Copland, M.; Walker, M.J.; Whetton, A.D.; Holyoake, T.L. Quantitative proteomics analysis of BMS-214662 effects on CD34 positive cells from chronic myeloid leukaemia patients. Proteomics, 2013, 13, 153-168.
246. Lobell, R.B.; Liu, D.; Buser, C.A.; Davide, J.P.; DePuy, E.; Hamilton, K.; Koblan, K.S.; Lee, Y.; Mosser, S.; Motzel, S.L.; Abbruzzese, J.L.; Fuchs, C.S.; Rowinsky, E.K.; Rubin, E.H.; Sharma, S.; Deutsch, P.J.; Mazina, K.E.; Morrison, B.W.; Wildon, L. Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl: protein transferase and geranylgeranyl: protein transferase type-I. Mol. Cancer Ther., 2002, 1, 747-758.
247. Available from: http://clinicaltrials.gov/show/NCT00004057? displayxml=true. Accessed on 25-04-2013.
248. Kim, C.K.; Choi, Y.K.; Lee, H.; Ha, K.S.; Won, M.H.; Kwon, Y.G.; Kim, Y.M. The farnesyltransferase inhibitor LB42708 suppresses vascular endothelial growth factor-induced angiogenesis by inhibiting Ras-dependent mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signal pathways. Mol. Pharmacol., 2010, 78, 142-150.
249. Available from: http://www.axonmedchem.com/product/1794lb 42708.html. Accessed on 22-04-2013.
250. Na, H.J.; Lee, S.J.; Kang, Y.C.; Cho, Y.L.; Nam, W.D.; Kim, P.K.; Ha, K.S.; Chung, H.T.; Lee, H.; Kwon, Y.G.; Koh, J.S.; Kim, Y.M. Inhibition of farnesyltransferase prevents collagen-induced arthritis by down-regulation of inflammatory gene expression through suppression of p21ras- dependent NF-κB activation. J. Immunol., 2004, 173, 1276-1283. (Pubitemid 38924306)
251. Chang, M.; Lee, S.H; Kim, H.J.; Koh, J.S.; Kim, A. Preclinical metabolism of LB42908, a novel farnesyl transferase inhibitor, and its effects on the cytochrome P450 isozyme activities. Bioorg. Med. Chem. Lett., 2012, 22, 3067-3071.
252. Dinsmore, C.J.; Bogusky, M.J.; Culberson, J.C.; Bergman, J.M.; Homnick, C.F.; Zartman, C.B.; Mosser, S.D.; Schaber, M.D.; Robinson, R.G.; Koblan, K.S.; Huber, H.E.; Graham, S.L.; Hartman, G.D.; Huff, J.R.; Williams, T.M. Conformational restriction of flexible ligands guided by the transferred noe experiment: potent macrocyclic inhibitors of farnesyltransferase. J. Am. Chem. Soc., 2001, 123, 2107-2108. (Pubitemid 32200052)
253. Palmioli, A.; Sacco, E.; Abraham, S.; Thomas, C.J.; Domizio, A.D.; Gioia, L.D.; Gaponenko, V.; Vanoni, M.; Peri, F. First experimental identification of Ras-inhibitor binding interface using a water-soluble Ras ligand. Bioorg. Med. Chem. Lett., 2009, 19, 4217-4222.
254. Ganguly, A.K.; Wang, Y.S.; Pramanik, B.N.; Doll, R.J.; Snow, M.E.; Taveras, A.G.; Remiszewski, S.; Cesarz, D.; del Rosario, J.; Vibulbhan, B.; Brown, J.E.; Kirschmeier, P.; Huang, E.C.; Heimark, L.; Tsarbopoulos, A.; Girijavallabhan, V.M. Interaction of a novel GDP exchange inhibitor with the Ras protein. Biochemistry, 1998, 37, 15631-15637. (Pubitemid 28524733)
255. Kelly, J.; Dominguez-Escrig, J.; Leung, H.Y.; Stephens, T.C.; Neal, D.E.; Davies, B.R. The prenyltransferase inhibitor AZD3409 has anti-tumor activity in preclinical models of urothelial carcinoma. Proc. Am. Assoc. Cancer Res., 2005, 46, abstract 5962
256. Stephens, T.C.; Wardleworth, M.J.; Matusiak, Z.S.; Ashton, S.E.; Hancox, U.J.; Bate, M.; Ferguson, R.; Boyle, T. AZD3409, a novel, oral, protein prenylation inhibitor with promising preclinical antitumor activity. Proc. Am. Assoc. Cancer Res., 2003, 44, R4870.
257. Song, S.Y.; Meszoely, I.M.; Coffey, R.J.; Pietenpol, J.A.; Leach, S.D. K-ras independent effects of the farnesyl transferase inhibitor L-744832 on cyclin B1/Cdc kinase activity, G2/M cell cycle progression and apoptosis in human pancreatic ductal adenocarcinoma cells. Neoplasia, 2000, 2, 261-272. (Pubitemid 30346082)
258. Manne, V.; Yan, N.; Carboni, J.M.; Tuomari, A.V.; Ricca, C.S.; Brown, J.G.; Andahazy, M.L.; Schmidt, R.J.; Patel, D.; Zahler, R. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells. Oncogene, 1995, 10, 1763- 1779.
259. Ghinet, A; Rigo, B.; Dubois, J.; Farce, A.; Hénichart, J.-P.; Gautret, P. Discovery of ferrocene-containing farnesyltransferase inhibitors. Investigation of bulky lipophilic groups for the A2 binding site of farnesyltransferase. Med. Chem. Comm., 2012, 3, 1147-1154